Cargando…

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study

BACKGROUND: Atrial fibrillation (AF) is an increasingly recognized codiagnosis in patients with cancer. OBJECTIVES: This study aimed to provide a robust and contemporary estimate on the coprevalence and relative risk of AF in patients with cancer. METHODS: We conducted a nationwide analysis, utilizi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ay, Cihan, Grilz, Ella, Nopp, Stephan, Moik, Florian, Königsbrügge, Oliver, Klimek, Peter, Thurner, Stefan, Posch, Florian, Pabinger, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986100/ https://www.ncbi.nlm.nih.gov/pubmed/36891526 http://dx.doi.org/10.1016/j.rpth.2022.100026

Ejemplares similares

Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
por: Königsbrügge, Oliver, et al.
Publicado: (2017)

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2018)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

ABO blood group type and risk of venous thromboembolism in patients with cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation
por: Nopp, Stephan, et al.
Publicado: (2023)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer
por: Moik, Florian, et al.
Publicado: (2020)

How I treat cancer-associated thrombosis
por: Moik, Florian, et al.
Publicado: (2020)

Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital
por: Nopp, Stephan, et al.
Publicado: (2020)

Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability
por: Ercan, Huriye, et al.
Publicado: (2021)

Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation
por: Königsbrügge, Oliver, et al.
Publicado: (2019)

Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study
por: Steiner, Daniel, et al.
Publicado: (2022)

Epidemiology, risk profile, management, and outcome in geriatric patients with atrial fibrillation in two long-term care hospitals
por: Wagner, Gernot, et al.
Publicado: (2022)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
por: Moik, Florian, et al.
Publicado: (2020)

Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status
por: Rejtő, Judit, et al.
Publicado: (2023)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality
por: Riedl, Julia, et al.
Publicado: (2014)

Outpatient Pulmonary Rehabilitation in Patients with Persisting Symptoms after Pulmonary Embolism
por: Nopp, Stephan, et al.
Publicado: (2020)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer
por: Moik, Florian, et al.
Publicado: (2022)

Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease
por: Posch, Florian, et al.
Publicado: (2019)

Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2020)

Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life
por: Nopp, Stephan, et al.
Publicado: (2022)

Low extracellular vesicle–associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis
por: Hell, Lena, et al.
Publicado: (2018)

Hemostatic biomarkers associated with postpartum hemorrhage: a systematic review and meta-analysis
por: de Moreuil, Claire, et al.
Publicado: (2023)

Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant
por: Posch, Florian, et al.
Publicado: (2017)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence
por: Nopp, Stephan, et al.
Publicado: (2022)

Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation
por: Hell, Lena, et al.
Publicado: (2021)

Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2019)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis
por: Hell, Lena, et al.
Publicado: (2020)

Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank
por: Mehic, Dino, et al.
Publicado: (2023)

Fibrinolysis and bleeding of unknown cause
por: Mehic, Dino, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vio4o310lg4ml1d5q0pt2v27ib